Analyst Price Targets — SPRY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 10:56 am | — | Northland Securities | $25.00 | $8.27 | TheFly | Northland starts disruptor ARS Pharmaceuticals with an Outperform |
| March 10, 2026 10:22 am | Roanna Ruiz | Leerink Partners | $26.00 | $9.28 | StreetInsider | ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners |
| November 4, 2025 12:53 pm | Kyle Bauser | Roth Capital | $30.00 | $8.42 | TheFly | ARS Pharmaceuticals resumed with a Buy at Roth Capital |
| September 26, 2025 2:02 pm | — | Raymond James | $32.00 | $9.69 | TheFly | Raymond James positive on ARS Pharmaceuticals after weekly data |
| August 19, 2024 5:06 pm | Josh Schimmer | Cantor Fitzgerald | $30.00 | $14.24 | TheFly | ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald |
| August 12, 2024 4:28 pm | Strong Buy | Raymond James | $22.00 | $10.85 | TheFly | ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James |
| July 25, 2024 6:30 am | Ryan Deschner | Raymond James | $18.00 | $10.40 | TheFly | ARS Pharmaceuticals initiated with an Outperform at Raymond James |
| March 5, 2024 6:07 am | Roanna Ruiz | Leerink Partners | $18.00 | $8.65 | StreetInsider | Leerink Partners Upgrades ARS Pharmaceuticals Inc (SPRY) to Outperform |
| December 13, 2022 6:10 am | — | Leerink Partners | $14.00 | $7.12 | Benzinga | SVB Leerink Initiates Coverage On ARS Pharmaceuticals with Outperform Rating, Announces Price Target of $14 |
Latest News for SPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, S
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number,…
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.
LOS ANGELES, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRY.
U.S. House Trading
No House trades found for SPRY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.